Please login to the form below

Not currently logged in
Email:
Password:

Zelluna appoints Miguel Forte as CEO

He joins the Norwegian biotech from Bone Therapeutics

Miguel ForteZelluna Therapeutics has appointed its new chief executive officer in the form of Miguel Forte.

His new role will see him lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.

Forte said: “Zelluna has a very strong foundation, based on over 30 years of cutting edge research.

“I wished to join Zelluna to combine my experience to the considerable potential of Zelluna to position is as an international immunotherapy leader and bringing serious therapeutic options to patients of the most common and fatal solid cancers.”

Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, Bristol-Myers Squibb, Abbott, and UCB to name a few.

Forte’s expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and is currently chief commercialisation officer and chair of the commercialisation committee for the International Society of Cellular Therapy.

Anders Tuv, chairman of the board, Zelluna, said: “Appointing a CEO with the international experience and profile of Miguel Forte will be critical to further enhance the therapeutic development and commercial potential of Zelluna, and push its leadership position in the international TCR and immunotherapy marketplaces.”

14th November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics